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Induction chemoradiation and complete surgical resection provide 
better survival for non-small-cell lung carcinomas of the superior 
sulcus
Tagawa, Tetsuzo; Yamazaki, Koji; Okamoto, Tatsuro; Kometani, 
Takuro; Wataya, Hiroshi; Seto, Takashi; Ichinose, Yukito 
National Kyushu Cancer Center, Fukuoka, Japan
Background: Non-small-cell lung carcinomas (NSCLC) of the 
superior sulcus are particularly challenging to treat because they often 
involve the spine, brachial plexus and subclavian vessels. Recently, 
combined modality therapy including induction chemoradiotherapy fol-
lowed by resection has improved outcomes of this tumor. 
Methods: We retrospectively analyzed the records of 61 patients with 
the superior sulcus NSCLC without distant metastasis at presentation 
who were treated initially in our institution between 1982 and 2007.
Results: Median age at presentation was 60 years (range 34 to 80 
years) and 53 patients (87%) were men. 33 patients (54%) had clinical 
T3 tumors while 28 (46%) had clinical T4 tumors. As to the nodal 
status judged by computed tomography of the chest, 36 (59%), 7 
(12%), 13 (21%) and 5 (8%) patients had clinical N0, N1, N2 and N3 
nodal status, respectively. Mediastinoscopy were not performed in all 
patients. The histologic subtype was adenocarcinoma in 28 patients 
(46%), squamous cell carcinoma in 20 patients (33%), large cell car-
cinoma in 9 patients (15%), and other subtypes in 4 patients (6%). As 
the initial therapy, 33 patients (54%) received concurrent chemoradio-
therapy, 19 patients (31%) received surgery, 8 patients (13%) received 
radiotherapy, and 1 patient received chemotherapy. Of the 33 patients 
who received concurrent chemoradiotherapy, mean total radiation 
dose was 50.0Gy, 32 patients received platinum based combination 
chemotherapy and 28 patients received surgery subsequently. Four 
patients received surgery after radiotherapy. The operations performed 
included 48 lobectomies and 2 penumonectomies and 1 exploratory 
thoracotomy. Combined chest wall resection was performed in 47 pa-
tients. Complete surgical resection was performed in 48 patients (79%). 
The postoperative mortality rate was 2.0% (1/51). Median follow-up 
time of all patients was 35 months. Overall 5-year survival rate was 
53.0%. The median survival time was 72 months. By univariate analy-
sis, chemoradiotherapy and complete resection signiﬁcantly affected 
overall survival. Five-year survival rate was 61.1% in 33 patients who 
received chemoradiotherapy and 61.7% in 47 patients who received 
complete resection. The median survival time was not reached in pa-
tients who received chemoradiotherapy and was 107 months in patients 
who received complete resection. Multivariate analysis identiﬁed that 
complete resection was the only factor signiﬁcantly associated with 
overall survival. The clinical T status and clinical N status did not cor-
relate with survival. 
Conclusions: The use of concurrent chemoradiation induction therapy 
may downstage tumors, enhance the ability to obtain a complete surgi-
cal resection, and prolong survival even in T4 or N2-3 patients.
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Phase II study of TS-1(S) plus cisplatin(P) with concurrent thoracic 
radiotherapy for unresectable stage III non-small cell lung cancer 
(NSCLC)
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Background: Although combined chemoradiotherapy is the standard 
of care in stage III NSCLC, the optimal chemotherapy regimen is 
not established. S-1, a fourth-generation oral ﬂuoropyrimidine is an 
active new agent for NSCLC and the combination with cisplatin has a 
favorable toxicity proﬁle. The objective of this study was to evaluate 
feasibility and efﬁcacy of S plus P with concurrent radiation for unre-
sectable stage III NSCLC.
Methods: Patients with histologically or cytologically conﬁrmed 
NSCLC, 20 to 75 years in age, performance status 0-1, with no prior 
chemotherapy were eligible for the study. Patients were treated with P 
(60 mg/m2 on day 1) and S (orally at 40 mg/m2/dose bid (80 mg/2/d), 
on days 1 to 14) repeated every 3-4 weeks for 4 cycles and TRT (60 
Gy/30fr over 6 weeks starting on day 2). The primary endpoint was the 
response rate (RR), and planned sample size for this phase II study was 
28 patients (Simon’s two-stage minimax design, P0=70%, P1=90%, α 
=0.1, β = 0.1).
Results: Of 28 patients enrolled between August 2005 and October 
2006, 28 were evaluable. There were 24 males and 4 females, median 
age of 63 (range 40-74) and 11 IIIA and 17 IIIB. Chemoradiotherapy 
was well tolerated; 2 cycles of SP and 60Gy of TRT were administered 
in all patients and 24 (86%) patients received 4 cycles of SP. During 
concurrent chemoradiotherapy, grade 3 toxicities were neutropenia (8 
pts), leukopenia (6 pts), fatigue (6 pts), anorexia (5 pts), febrile neutro-
penia (4 pts) and, esophagitis (4 pts). Only one grade 4 leukopenia were 
observed. During consolidation therapy, grade 3-4 neutropenia, anemia, 
esophagitis, and pneumonitis were developed in 4, 1, 1 and 2 patients, 
respectively. No toxic deaths have occurred.Overall RR was 85.7% 
(95%CI: 79.1-98.7%) with 4 SDs and 24 PRs. The median progression-
free survival and median survival is not mature enough to estimate as 
only 4 progression and no deaths have occurred.
Conclusions: This chemoradiotherapy regimen produced promising 
response rate in patients with stage III NSCLC and it seems to be well-
tolerated.
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A phase II study of daily gefitinib plus weekly paclitaxel (GP) in 
Taiwanese non-small cell lung cancer (NSCLC) patients who failed 
gefitinib (G) or both G monotherapy and taxane (T) treatment
Tsai, Chun-Ming; Lai, Chun-Liang; Chiu, Chao-Hua; Liou, Jia-Ling; 
Chang, Kuo-Ting 
Section of Thoracic Oncology, Chest Department, Taipei Veterans Gen. 
Hospital, Taipei, Taiwan
Background: G, an epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitor, is an active agent in subgroup of NSCLC patients (pts) 
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and also has in vitro blocking activity to ATP-binding cassette (ABC) 
transporters. We evaluated the activity and toxicity of GP in NSCLC 
pts who failed prior G or both G and T (G/T). 
Methods: Eligibilities were NSCLC failed G, measurable lesion, 
ECOG PS0-3 and life expectancy > 6 wks. They were chemonaive 
or had failed prior chemotherapeutic regimen(s)(CTR). Treatment 
consisted of oral G (250 mg) daily and intravenous P (60 mg/m2) d1, 
8, 15 q4w. Primary endpoint was response rate (RR) and secondary 
endpoints were disease control rate (DCR), time to progression (TTP), 
overall survival (OS) and toxicity. GP was also tested in vitro in an 
adenoca. cell line with wild type EGFR and its p-glycoprotein (pgp) 
expressing subclones. 
Results: From Sep 2004 to Mar 2007, 53 pts were enrolled and eligible 
for activity and toxicities: M/F 21/32; median age 64; PS 1/2/3 25/25/3; 
stage IIIB/IV 5/48; adeno/squ/others 44/4/5. Of the 53 pts who failed 
G, 10 were chemonaive, 8 had prior G and non T agents, 35 had prior 
G/T (docetaxel 28, paclitaxel 11). Median prior CTR was 3 (0-6). A 
total of 436 cycles (median 6, range 1-18) were given. RRs were 22.6% 
and 22.9%, DCRs (PR+SD) 45.3% and 45.7%, TTP 135d and 99d, OS 
265d and 233d for overall and G/T groups, respectively. There was a 
trend that prior T resistant pts may have better response than T refrac-
tory ones. G3/4 toxicities were leukopenia 4% and 3%, anemia 2% and 
3%, G3 ﬂu-like symptoms 16% and 14% in overall and G/T group, 
respectively. In vitro drug testing showed that G could reverse Pgp as-
sociated P resistance in a dose dependent fashion. 
Conclusions: GT showed a moderate activity for salvage treatment 
in pts who failed prior G or G/T. G may aid P or partially reverse its 
resistance. 
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Electrocautery in combined modality with chemotherapy and 
radiotherapy in treatment of non-small cell lung cancer affecting 
central airways
Tudik, Ivan 
Specialized Hospital of Respiratory Diseases, Poprad, Slovakia
Background and Methods: Electrocautery (EC) is a method that uses 
alternating current for thermal destruction of tissue. Depending on the 
voltage and current, electrocautery causes coagulation or vaporiza-
tion and carbonization of tissue. During the period 08/2002 - 02/2007 
electrocautery in local anesthesy was used in treatment of 37 pts. with 
various indications. The author presents results of treatment in 14 
patients with inoperable locally advanced non-small cell lung cancer 
predominantly expanding to central airways with only insubstantial 
affecting lung parenchyma and with no metastases (S IIIB). In these 
patients, electrocautery (EC) was combined with chemotherapy (CHT) 
and radiotherapy ( RAT ) or brachyradiotherapy. The ﬁrst dose of 
CHT was given just within the 1st day after EC, preferably platinum 
regimens (CDDP- Vinorelbine 5x, CDDP- Vinblastine 2x, CarboPt 
- Gemcitabine 2x, Vinorelbine monotherapy 2x, Docetaxel 2x, Gemzar 
monotherapy 1x). EC and CHT was used in the ﬁrst-line treatment in 8 
pts. and in the second-line in 6 pts. with relapsed NSCLC. EC was used 
on average twice in one patient ( min. 1, max. 3 ) during the treatment 
time. 
Results: Recanalization of central airways was achieved in all patients 
(100%), complete recanalization was achieved in 6 pts. out of 8 (75%) 
where EC and CHT was used in the ﬁrst-line setting. Treatment can 
be effective even in case of massive endotracheal or endobronchial 
lesions. The overall median survival time was 13 months ( 95% CI 0,0 
- 26,9), median survival time in subgroup of 8 pts., where EC was used 
in the ﬁrst-line setting, was not reached. EC and CHT can be easily and 
safety combined, there were found no 30 days mortality and minimal 
morbidity.
Discussion: There is only limited amount of information regarding 
positive effect of combined EC (or other method of interventional bron-
chology) and CHT/RAT (1,2). A synergic effect of both the methods 
is possible. One explanation for this effect could be the action of heat 
shock proteins, that are regarded as possibly the most potent stimulans 
of immune response in oncology and are used for development of anti-
cancer vaccines (3,4). The other explanation is the thermal pre-impair-
ment of deeper structures of a tumor which facilitates the better action 
of cytostatics. 
Conclusions: Fiberbronchoscopic electrocautery under local anesthesia 
is an effective and safe method in treatment of patients with inoper-
able central NSCLC, which can be used in combined modality with 
chemotherapy and radiotherapy. A synergic effect of electrocautery and 
chemotherapy is possible.
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Radiation pneumonitis (RP) in lung cancer patients treated with 
chemotherapy (CT) and thoracic radiation (TR): Retrospective 
analyses of patients treated at a comprehensive cancer center
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Background: Combined CT and TR is the current standard for locally 
advanced non-small cell lung cancer (NSCLC) and SCLC. Severe 
RP, an important adverse effect of TR, is reported in clinical trials to 
occur in 10% of patients receiving CT and TR. The rate in routine care 
may be higher as patients are not selected based on lung function. We 
conducted a retrospective study to assess the incidence of RP in lung 
cancer patients treated with CT and TR.
Methods: Retrospectively we identiﬁed patients who underwent com-
bined modality therapy (concurrent or sequential CT and TR) for lung 
cancer (NSCLC & SCLC) at our cancer center between January 2001 
and December 2004. Demographic features, RP incidence and grade 
(RTOG criteria), hospitalization rate, and overall survival (OS) were 
assessed.
